Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI.
iGlarLixi(Insulin Glargine 100 U/ml 和 Lixisenatide)在2型糖尿病(T2D)患者中根據基線 HbA1c 和 BMI 的實際效果。
Diabetes Ther 2024-09-14
Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk.
哺乳期間使用皮下 Semaglutide:藥物轉移至人乳的嬰兒安全性。
Nutrients 2024-09-14
Investigation of Glucose Metabolism by Continuous Glucose Monitoring and Validation of Dipeptidyl Peptidase 4 Inhibitor Use in Patients with Myotonic Dystrophy Type 1.
透過持續血糖監測調查葡萄糖代謝及驗證二肽基肽酶 4 抑制劑在肌強直性肌肉萎縮症 1 型患者中的使用。
J Clin Med 2024-09-14
Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.
慢性腎病及第二型糖尿病患者中新型口服 Semaglutide 配方的療效與安全性之實際研究。
J Clin Med 2024-09-14
Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management.
GLP-1 受體激動劑在 1 型糖尿病管理中的機制途徑及臨床意義。
Int J Mol Sci 2024-09-14